Drug intelligence / Profile preview

miconazole nitrate + zinc oxide

Development stage: Approved
Lead developer: Viatris
Modality: Small Molecules, Transdermal Patches → Device-based Delivery → Drug Delivery Systems, Hydrogel Systems → Drug Delivery Systems
Administration: Topical

Overview

A topical combination medication primarily used to treat diaper rash complicated by fungal infections. This topical preparation combines the antifungal properties of miconazole with the protective and soothing effects of zinc oxide. Specifically indicated for the adjunctive treatment of diaper dermatitis only when complicated by documented candidiasis (yeast infection). It is approved for use in infants 4 weeks of age and older with normal immune systems.

Brand names: VusionRash Relief AntifungalDaktozin
Other names: miconazole nitrate, zinc oxide, and white petrolatum

Targets

CYP51A1 (Sterol 14α-demethylase)

Beyond the preview

Go deeper on miconazole nitrate + zinc oxide.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on miconazole nitrate + zinc oxide.

Explore the full profile